Rates and predictors of embolic events following electrical cardioversion  by Gentile, F. et al.
We measured hpopretoms, low.density hpoprolem (LDL) subclasses and 
part,tie size, hpopreloin (a), homocystemo (Hcys), and markets of thremboszs 
and fibnnolysis in 22 oealthy o!derly men ~ago 74 ~ 3 years, mean 
SO), before and alter 9 weeks of treatment with 05, t n, ~ mg,'day O1 oral 
m~cromted 17/~-estradiol 
Restdt~: LDL-C I-6%), apo.B ( 9%), fnglyceride ( 5%), VLDL-TG 
( - ! 9%) 8nd Ho/s ( - 11%) coneenffahons decreased w~th estradtot, whereas 
HDL-C (*14%) and HDL~-C (*55%) increased Lipoprotein (a) d~d not 
ch,~nge. Fibenogen (13%)  and p!asmln(~gen activator inhibitor.1 (PAl.l) 
(26%)  C~noeflf~ations decreasecl There were no changes ~n thrombotK: 
matkem including thrombln-ant!thrembm I!1 complex, prothrombm fragment 
t 2, O.dim0r, anhthfombm activity, preteln~C an~ S and yon Willebrand factor 
set!pen 
Va~btes Pte-eli1~ogen PO-~t~E~OO~I~, % Ch~lnge p vah~e 
(rne<tn ~ SD) irl~an ~ SOl 
LDL-C~t  14t ~ 2t] 132 ~ 30 63 ~ 12 = 0007 
IG mgd~ t30 s ~ 11.~ ~ 41 4 7 ~. ~0 : O 01 
HDL.C ~.'dt 47 t 0 S3 t I0 .t4 z 12 -1) 001 
HDL3.C n~'~l 23 ~ 13 29 ~ 13 .55 : 72 -0003 
HDL3"C m~2/dl 30 ~ ? 27 ~ (~ a 4 ~ tO ; 0 001 
LOLs~e (nml 207 ~O6 2oa ~ 06 9fi ~ a o0ot 
Hc'y~ ti,M) 67 ~ 3 76 ~ 2 I 1., 09 - OOOt 
CortCtu$iOn. We conclude that k'~v (~se estrogen in men reduces low-den- 
sity hpoprotems, homom/steine tibnn(~en and PlA-1 concentrations w~thout 
.ncfeas=ng markers of thrombotic ~sk 
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~ Lipoprotein(a), Stability of Coronary Reperfuslon 
and Efficacy of Thrombolytic Therapy 
AW Harder. G.J. Davies. Card~otogy D~.~s~en. RPMS Hammersm~th 
HOSl~tal London. UK 
Background: Lq:~,c'~retemt:t~ ',Lpa) promotes atherothrembos=s, however, stud- 
~es dunncj acute my~T, ard~al ..-ttarct=on (AMI) remain mcenclusnte We mves- 
bgatecl the relationship between Lpa and efficacy O1 thromb~lyl~c therap'y 
dunng AM= 
,~c-~; :  Twenty six patients 117 men. 9 women, mean age 57 : 2 years) 
admitted with AM| re~mved i v t-PA (30-60 Mega Units) w~thm 6 hours at the 
onset of Symptoms Coronary recanai=zat~on (TIMI grade 3) was assessed 
by senal adenography and ~n~nuou~ 2 channel ST segment recording was 
used to momtor the stabddy of coronary reperfusmn All pat~enLs received 
oral aspmn and =v hepann Baseline pretreatment Lpa and serum hp~d 
~eveLs were measu(.'~cl Patients ,~ere dtvldecl =n 2 groups: Group 1 ILpa 
levels ::25 mg.,'dl, n = 12) and Group 2 ILpa levels - 25 mg.'dl, n = 14) 
Resuits Age. sex. treatment delay from symptom onset. 90 minute TIMI 
grade and hp=ds levels ~ere similar ~n the 2 groups However. coronary 
recanahzafton time (mean : SD) was significantly prolonged cn group 1 
compared to patients m group 2 t51 = 16 vs 30 ; 17 rain p = 005) 
Recanalizahon t~me correlated pos=hvely w~th Lpa levels (r . 0.9. p ~ 0001 ). 
The number (5 : 1vS. 1 =05.  p - 002) and magmtude (31 ~: 1 mmvs. 
1.2 ~ 1 ram. p .  005) OI recurrent ST elevahon following thrombelysls was 
greater m grOup 1 cOmpared to group 2 
Conclusions: Elevated Lpa =s assooated with delayed and unstable coro- 
naw repedus~on toltowmg ~ v tPA 
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[ 845- i_~ I Rates and Predictors of Embolic Events Following 
Electrical Cardloverslon 
F. Genhle, B.K. Khandhena, KR. Bailey. C Lohse. J.8. Seward. A Jamd 
Taiik. Mayo Chn~c and M,tVO Foundat;on. Rochester. Mmnesota. USA 
Wide vanations (1-7%) in reported rates of embolic events lEE) following 
electrical cardioversion (ECV) exist in the literature. To evaluate EE nsk in 
the Mayo ECV practice, all ECVs (1053. 66% male. mean age 66 = 12.5 
years) between 1990-1994 were studied. Patient as well as atrial tibnllafion 
and anticoagulation (AC) characteristics were recorded. Adequate AC was 
defined as therapeutic International Normalized Ratio / Partial Thromboplas- 
tin -time. AC consisted of warfarin (63.0%). heparin (118%). born (15.9%), 
and none (9.3%). Successful ECV was achieved in 892 pts (85%) who form 
the basis for analysis. The rat3 of EE occurrence within 30 days was 0.78% 
(CI 0.32-1.62%). Two (2.1%) of these occurred in 94 no-AC pts (p = 0.012 
compared to AC pts) The rates of EE wore 027% m ad~uatety ant=co. 
agulated pls versus 1 68% ,n m~dequatety anllcoagutated pts (p = 0 0491 
All 7 events occurred =r, the 51% pts with hypedens~on (p = 0 OCt. ) Four 
occurred in 142 diabetic pts iP 0 001 ) History of coronary affery d~sca~.c~ 
and hyperl=p=dem~& were also segndcant (p 005) corretat~ ot EE Two 
O1 7 events OCCurred among 31 pts with severe letl atna! enfarsement (p .  
0 05) 
Cantles!ads 1) Ovmal! rate of EE following ECV m 0 78%= 2) adequate 
AC at the t~me O1 ECV results in lower rates o1 EE (027%); 3) hypertens~Onr 
d~abetes, and severn loft at~!! enla~rgement am associated with h igher  rates 
O1 EE following ECV: and 4) higher rates of EE (2 t%) are noted m pt~ 
not re~oiwng any AC ECV is ~ safe procedure when pts are adequately 
anl=coagutated 
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~ Hypertens!on Strongly Predict= Early Relapse Atter 
Elective Card!ovemlon of Air!a! Fibrillation 
L O'Toele, A. Wilhams, TR D ,Shaw, IR  Starkey, DB Nodhndge Depfot 
Card~o/og~, Western General Hosl~fat, Ec~nburgh. UK 
Background There h~ been a marked recent mcrea~e =n the use O1 electwe 
DC Cardmvers=on IDCCV) for atnal flbnllstlon (AFt We reviewed our pract*ce 
dunng 1996 to identdy chmcal factors which predict maintenance ol sinus 
rhythm (SR) at st~, week follow up (FU) 
Method: Case note rewew of 88 elective admms~ons for DCCV 
Results: 40% O1 patients had hyperlens=on (PIT) 40'% O1 patients were 
taking am~octarone peer to DCCV Immediate mstoratfon at SR was ach~evecl 
=n 88% O1 attempts but only 47% ot the tctat had maintained SR at FU 
In the 63 patrents undergoing DCCV for the first time, tact'ore pred,.ctmg 
maintenance of SR at FU were re~ewecl Age. sex, the presence ot CAD. 
impaired LV function ard use at digoxln did not predict mmntenance at SR 
3=;.~,*.~n .-,I AF ~rongty predicted maintenance O1 SR at FU (AF clura0on - 6 
months 84%. • 6 montt's 32%; p ~ 0 001 ) as did a d=agnos~s of PiT (SR at FU 
PIT 27%, non-HT 70%; p ~ O001) and use et amiodarene (SR at FU 74% 
vs 38%, p = 0002) After adiustment for durahon of AF or use O1 am~odarone 
the relabonsh~p between a diagnosm of HT and tadure to maintain SR at FU 
became even stronger (duration ac~Jsled odds rat~o; HT vs non-HT pat=eats 
12.6; p - 0.001 amlodarone adius~ed odds rat~o .54: p = O 004) 
Cencl'.~on The pr~pomon O1 I-IT patients cn th~s senes =s h~ghe[ than 
reported pre'.qousty, but similar to that m population-based studies of AF The 
chance of maintaining SR after DCCV =n HT patients =s unacceptably low 
Measures to improve outcome include early DCCV and pre-treatment with 
am~oclarene 
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~ 845-3  i The  Cl inical  Exper ience  With the Metr lx Automat ic  
' Imp lantab le  Atr ia l  Def ibr i l lator  
R Tavem~er, L Jordaens For the Metnx Ir~,est~gators. Umversffafr 
Z~ekenhu~s Gent. Gent. Belgium 
Transven~us atnal defibnllahon has been shown to be efficacious for the 
acute termination of episodes of areal fibnllal~on (AF). However, no data 
exist as fo whether repeated transvenous defibnllatlon using an aulomstlC 
cmplantable atrial defibnllator (laD) would be efficamous. Therefor~ the pur- 
pose O1 this chmcal teal was to evaluate the clinical use O1 the Metnx lAD 
m patients (pts) with uprsod~c, symptomatic AF refrecto~/ tO drug therapy. 
The device and Its 3 leads system (Penmeter nght sinai, Penmeter cereno~ 
sinus delibnllat~on and right ventncular bipolar leads) were ~mplanted in St 
pts (40 mares and 11 females). On average these patients had taken 39 
ant~arrhylhm~c drags that had fa~led to control AF recurrence or were found 
to have intolerable s~de effect These pts were without significant StruC~urat 
head d~sease and shghtly enlarged nght stnum (mean LA size 4 4 ~ 0 8 
cm). Dunng the study penocl of 20 months (mean pt follow-up 259 : 138 
days), 41 pts have exbenenced 252 spontaneous AF episodes (SE) with 
an average of 6 episodes per patient Excluding the throe epcsode5 that 
were !rested dunng ADFT testing. 675 synchron=zc"d shocks have been de- 
livered for the remmmng 249 SE (average 27 shocks per epcsode) with no 
ewdenoe of ventncutar prearrhythm~a One pstcent had a shock dehvered 
and had subsequent spontaneous conversion pnor to full delivery of ther- 
apy. One pabent had 4 SE where AF recurred shodly after the sucCesstul 
conversions. Three of these episodes were terminated with pharmacologi- 
cal interventions and one episode was terminated spontaneously. D~l;~ from 
these 8 episodes, including the 3 treated dunng ADFT testing, were ex- 
cluded =n the efficacy calculabons. The device has successfully terminated 
95=0 of the episodes although some patients had AF recurrence ~hortty ~; 
tar successful detibnllation. Taking th~s recurrence of AF into consideret¢on. 
the clinical efficacy of the defibnllat~on therapy was 77.4%. One pabent. 
due to frequent SE (1-2 per week) unaffected by the device unden,~ent AV 
junctional ablation with permanent pacing Prompt termmatren of AF has 
